Nemaura Medical Inc.

(NMRD)

ROTH Conference Presentation

March 11^th 2015

1

Presentation Overview

2

Our Background

•

Founded in January 2009 by Dr D F Chowdhury, the majority shareholder and the CEO

•

Biotech diagnostics research focused, headquarters in United Kingdom

•

Research facilities location at Science Park, Loughborough University, UK

•

Proprietary technology on transdermal (works through the skin) applications

•

diagnostic technologies

•

drug delivery technologies

•

Owned a family of related patents across various continents

•

Monitor commercialization process through sub-contracting to expert production and marketing vendors

•

Trading on NASDAQ OTC BB ticker: NMRD

3

Key events

4

Our Core Business

Platform technology developed for Drug Delivery and Diagnostic Applications.

Current Focus: (Diagnostic Applications)

Non-invasive, continuous and painless monitoring of analyte / molecules. For example: glucose, lactate, prescription drugs.

Future Focus: (Drug Delivery)

Drug Delivery complementing diagnostic application.

For example, non invasive insulin delivery working in tandem with non invasive continuous glucose monitoring.

5

Management Overview

Core Team of 21 People consisting of:

•

5 Board Members

•

4 Science Advisory Team Members

•

12 Technical Team Members

CEO: Dr D F Chowdhury: Microsystems and Nanotechnology from Cranfield University and PhD from the University of Oxford in nano-drug delivery; over 18 patents pending/granted.

CFO: K Farrar: MChem from University of Oxford, Chartered Accountant, 10 years with KPMG.

CTO: Prof. K. Khan: Launched over 60 products during his career in the Pharmaceutical Industry.

Medical Device & Regulatory Director: R Carson – A Pharmacologist with 20+ years experience in medical device design and registration in Europe and US.

6

Government Support

Recipient of over $2m in several separate UK government grants awarded under independent competitive tendering process.

Grants awarded by UK Government Technology Strategy Board. Independent government assessor quoted:

‘The product could be a game changing technology’.

7

Our Patents

Patents granted:

Patents submitted:

8

sugarBEAT™ Product

Our first commercialized product

sugarBEAT™

9

sugarBEAT™ Product

sugarBEAT™ consists of three parts;

1.

a disposable patch (“Patch”)

2.

bluetooth enabled device (“Device”)

3.

smart phone app (“App”)

To use sugarBEAT™:

1.

Affix Patch to arm

2.

Connect Patch to adjacently worn Device via thin wire

3.

Device transmits real time data to App

4.

App can send data online to remote health care team

sugarBEAT™ provides up to 4 readings an hour for 12 hours or more.

10

sugarBEAT™ Product – How it Works

11

sugarBEAT™ Product - Clinical Need

•

Diabetics suffer from unstable blood glucose levels

•

Diabetics therefore need to constantly monitor glucose levels.

•

Currently the most common monitoring method involves:

•

Extracting a drop of blood (droplet) by piercing the skin (finger pricking) several times a day.

•

This droplet is placed onto a test strip to provide a glucose reading.

•

Other methods require intrusive insertion into subcutaneous tissue.

•

The test strip market alone is currently generating over $10 Billion sales per annum.

•

There is huge demand for our non – intrusive and continuous monitoring method, which is convenient, timely and painless.

•

Our method will also provide substantial savings to diabetic patients.

12

•

sugarBEAT™ Product – Image of Device

13

sugarBEAT™ Product – Illustration of AP

14

Our Technology - sugarBEAT™

Technical basis:

•

Works by passing a mild current across the skin that is barely perceptible, or non-perceptible.

•

This current pulls the glucose out of interstitial fluid, which is found just below the top layer of skin, into a reservoir in the patch.

•

The patch contains a sensor, which measures the amount of glucose analyzed.

•

An algorithm within the device converts this reading to a glucose concentration value.

•

This reading is displayed on the device with sound and / or buzzer alert

15

Our Clinical Trials for sugarBEAT™

16

Regulatory Approval for sugarBEAT™

CE mark applied for which will permit sales in:

•

European Union countries

•

Saudi Arabia

•

Honk Kong

•

US and Japan Regulatory Approval to be sought 2016 onwards

17

Target Market Analysis for sugarBEAT™ Product

18

Why sugarBEAT™ better than competition?

Competitors using invasive continuous technology have the following cons:

•

Cost – much more expensive

•

User market – mostly only suitable for type 1 diabetics which are only 10% of total diabetic market

•

Comfort – all require the continuous insertion of a measuring device into the body tissue which has high degree of user discomfort

19

Why sugarBEAT™ better than competition?

Competitors using finger prick technology suffer following cons:

•

Finger prick is painful

•

Finger prick is not continuous – most users only finger prick 1-2 times a day even though WHO recommends 5-7 times a day

20

Commercialization Process for sugarBEAT™

•

Manufacturing Development of Devices – Q2-Q4 2015

•

Manufacturing Development of Patches – Q2-Q4 2015

•

Mobile App development and launch – Q4 2015

•

Product Launch in HK, Saudi Arabia – Q4 2015

•

Product Launch in UK – Q1 2016

21

Production and Operations for sugarBEAT™

We are dedicated R&D company.

All manufacture and sales therefore subcontracted to expert partners.

Preferred partners selected for:

•

Device manufacture

•

Sensor Manufacture

•

Patch Manufacture

•

Electronics

22

Sales & Distribution for sugarBEAT™

Criteria for selecting specialist partners: (partner already selected for UK)

23

Financial Forcasts for sugarBEAT™

24

Our Future Potential – Drug Delivery

Works by inverting technology so drugs delivered non-invasively into skin via a reservoir in the patch.

Technology suitable for:

•

Programmed drug delivery

•

On-demand drug delivery

•

Chrono-therapeutic drug delivery

•

Closed loop diagnostic and drug delivery

•

Basal Insulin expected to be first product chosen

25

Contacts

26